A5054682698- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Gut microbiota and health
- Head and Neck Surgical Oncology
- Cancer Diagnosis and Treatment
- Esophageal Cancer Research and Treatment
- Nutrition and Health in Aging
- Immunotherapy and Immune Responses
- Pancreatic and Hepatic Oncology Research
- Salivary Gland Tumors Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Gastric Cancer Management and Outcomes
- Lung Cancer Research Studies
- Immune cells in cancer
- Cytokine Signaling Pathways and Interactions
- Lymphoma Diagnosis and Treatment
- Cancer Research and Treatments
- Frailty in Older Adults
- Cancer Cells and Metastasis
- Dysphagia Assessment and Management
- Oral health in cancer treatment
- Biosimilars and Bioanalytical Methods
Institut Català d'Oncologia
2015-2025
Institut d'Investigació Biomédica de Bellvitge
2015-2024
Duran i Reynals Hospital
2020-2024
Institut Català d'Ornitologia
2021-2024
New York Medical College
2024
Princess Margaret Cancer Centre
2018-2023
Universitat de Barcelona
2016-2023
University Health Network
2020-2023
University of Toronto
2018-2021
Bellvitge University Hospital
2017-2021
Abstract Serial circulating tumor DNA (ctDNA) monitoring is emerging as a non-invasive strategy to predict and monitor immune checkpoint blockade (ICB) therapeutic efficacy across cancer types. Yet, limited data exist show the relationship between ctDNA dynamics genome microenvironment in patients receiving ICB. Here, we present an in-depth analysis of clinical, whole-exome, transcriptome, profiles 73 with advanced solid tumors, 30 types, from phase II basket clinical trial pembrolizumab...
The intestinal microbiome has been associated with response to immune checkpoint inhibitors (ICIs) in humans and causally implicated ICI responsiveness animal models. Two recent human trials demonstrated that fecal microbiota transplant (FMT) from responders can rescue responses refractory melanoma, but FMT specific limitations scaled use.We conducted an early-phase clinical trial of a cultivated, orally delivered 30-species microbial consortium (Microbial Ecosystem Therapeutic 4, MET4)...
Abstract Background Oral and gut microbiomes have emerged as potential biomarkers in cancer. We characterised the oral a prospective observational cohort of HPV+ oropharyngeal squamous cell carcinoma (OPSCC) patients evaluated impact chemoradiotherapy (CRT). Methods Saliva, swabs over tumour site stool were collected at baseline post-CRT. 16S RNA shotgun metagenomic sequencing used to generate taxonomic profiles, including relative abundance (RA), bacterial density, α-diversity β-diversity....
Background Sitravatinib, a tyrosine kinase inhibitor that targets TYRO3, AXL, MERTK and the VEGF receptor family, is predicted to increase M1 M2-polarized tumor-associated macrophages ratio in tumor microenvironment have synergistic antitumor activity combination with anti-programmed death-1/ligand-1 agents. SNOW window-of-opportunity study designed evaluate immune molecular effects of preoperative sitravatinib nivolumab patients oral cavity squamous cell carcinoma. Methods Patients...
Activation of leukemia inhibitory factor (LIF) is linked to an immunosuppressive tumor microenvironment (TME), with a strong association between LIF expression and tumor-associated macrophages (TAMs). MSC-1 (AZD0171) humanized monoclonal antibody that binds high affinity LIF, promoting antitumor inflammation through TAM modulation cancer stem cell inhibition, slowing growth. In this phase I, first-in-human, open-label, dose-escalation study, monotherapy was assessed in patients advanced,...
Immune checkpoint blockade (ICB) has become a standard of care in the treatment recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC). However, only subset patients benefit from treatment. Quantification plasma circulating tumour DNA (ctDNA) levels on-treatment kinetics may permit real-time assessment disease burden under selective pressures treatment.R/M HNSCC treated with systemic therapy, platinum-based chemotherapy (CT) or ICB, underwent serial liquid biopsy sampling....
2502 Background: AhR activation is involved in tumor growth, immunomodulation, and resistance to immune checkpoint inhibitors. BAY2416964 a novel, potent, oral inhibitor (AhRi) that antagonizes ligand-induced immunosuppressive effects, resulting enhanced proinflammatory activity of antigen-presenting cells T reduced myeloid cells. Methods: A first-in-human, Phase I clinical trial AhRi (NCT04069026) evaluating its safety, pharmacokinetics, pharmacodynamics, recommended II dose, anti-tumor per...
Abstract Immune checkpoint blockade (ICB) approaches have changed the therapeutic landscape for many tumor types. However, half of cutaneous squamous cell carcinoma (cSCC) patients remain unresponsive or develop resistance. Here, we show that, during cSCC progression in male mice, cancer cells acquire epithelial/mesenchymal plasticity and change their immune (IC) ligand profile according to features, dictating IC pathways involved evasion. Epithelial cells, through PD-1/PD-L1 pathway,...
Background Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted 8th edition AJCC TNM (ICON-S model). However, it is still unclear HPV-relatedness definition best diagnostic accuracy prognostic value. Material methods The aim this study was to compare staging system models proposed patients: 7th TNM, RPA non-anatomic factors (Princess...
Background Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal index (SMI) on prognosis and immune-related adverse events (IrAEs) a cohort recurrent/metastatic (R/M) head neck squamous cell carcinoma (HNSCC) treated immune checkpoints inhibitors (ICI). Methods A single-institutional, retrospective study was performed including 61 consecutive patients R/M HNSCC diagnosed between July 2015 December 2018. SMI...